Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.43 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.43 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.40 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.40 |
| ▸ | CD274 | Q9NZQ7 | 12/20 | 0.34 |
| ▸ | PDCD1 | Q15116 | 10/20 | 0.34 |
| ▸ | PDCD1LG2 | Q9BQ51 | 2/20 | 0.34 |
| ▸ | CRBN | Q96SW2 | 2/20 | 0.33 |
| ▸ | CCNC | P24863 | 1/20 | 0.33 |
| ▸ | CDK8 | P49336 | 1/20 | 0.33 |
| ▸ | CDK19 | Q9BWU1 | 1/20 | 0.33 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16565923 | 0.84 | CYP11B1 (0.46) | SMN1; SMN2CYP11B1CYP11B2OPRM1OPRL1 | |
| SCHEMBL17166457 | 0.81 | TSHR (0.41) | SMN1; SMN2CYP11B1CYP11B2OPRM1OPRL1 | |
| SCHEMBL25051581 | 0.81 | TSHR (0.41) | SMN1; SMN2CYP11B1CYP11B2OPRM1OPRL1 | |
| SCHEMBL25051602 | 0.81 | TSHR (0.41) | SMN1; SMN2CYP11B1CYP11B2OPRM1OPRL1 | |
| SCHEMBL25975368 | 0.79 | CYP11B1 (0.35) | SMN1; SMN2CYP11B1CYP11B2OPRM1OPRL1 | |
| SCHEMBL8008730 | 0.79 | CYP11B1 (0.48) | SMN1; SMN2CYP11B1CYP11B2OPRM1OPRL1 | |
| SCHEMBL27054569 | 0.79 | CRBN (0.37) | SMN1; SMN2CYP11B1CYP11B2OPRM1OPRL1 | |
| SCHEMBL21506992 | 0.79 | CD274 (0.40) | SMN1; SMN2CYP11B1CYP11B2OPRM1OPRL1 | |
| SCHEMBL23260104 | 0.78 | SMN1; SMN2 (0.39) | SMN1; SMN2CYP11B1CYP11B2OPRM1OPRL1 | |
| SCHEMBL4289914 | 0.78 | SMN1; SMN2 (0.50) | SMN1; SMN2CYP11B1CYP11B2OPRM1OPRL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024020419-A1 | AZA-QUINAZOLINE COMPOUNDS AND METHODS OF USE | IAMBIC THERAPEUTICS, INC. (US) | 2024-01-25 | — | — | WO | disclosed |
| EP-4310084-A1 | PYRIDOPYRIMIDINE-BASED COMPOUND AND APPLICATION THEREOF | Jinan University (CN) | 2024-01-24 | — | — | EP | disclosed |
| WO-2023154282-A1 | COMPOUNDS HAVING A T-STRUCTURE FORMED BY AT LEAST FOUR CYCLES FOR USE IN THE TREATMENT OF CANCER AND OTHER INDICATIONS | THERAS, INC. (US) | 2023-08-17 | — | — | WO | disclosed |
| WO-2023125486-A1 | SOMATOSTATIN RECEPTOR SUBTYPE 5 ANTAGONISTS, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF | 中国科学院上海药物研究所 | 2023-07-06 | — | — | WO | disclosed |
| WO-2023016521-A1 | SUBSTITUTED TRIAZOLE DERIVATIVE, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF | 上海赛默罗生物科技有限公司 | 2023-02-16 | — | — | WO | disclosed |
| US-20230029385-A1 | 2-METHYL-AZA-QUINAZOLINES | BAYER AG (DE) | 2023-01-26 | — | — | US | disclosed |
| EP-3863713-B1 | PHENYLTETRAZOLE DERIVATIVES AS PLASMA KALLIKREIN INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2023-01-25 | — | — | EP | disclosed |
| US-20210387963-A1 | PHENYLTETRAZOLE DERIVATIVES AS PLASMA KALLIKREIN INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2021-12-16 | — | — | US | disclosed |
| WO-2021159993-A1 | INHIBITORS OF INTERLEUKIN-1 RECEPTOR ASSOCIATED KINASE (IRAK) /FMS-LIKE RECEPTOR TYROSINE KINASE (FLT3), PHARMACEUTICAL PRODUCTS THEREOF, AND METHODS THEREOF | PHARMABLOCK SCIENCES (NANJING) , INC. (CN) | 2021-08-19 | — | — | WO | disclosed |
| US-11034696-B2 | Compounds for inhibiting LRRK2 kinase activity | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2021-06-15 | — | — | US | disclosed |
| WO-2020025030-A1 | PREPARATION AND APPLICATION OF AROMATIC COMPOUND HAVING IMMUNOREGULATORY FUNCTION | 上海轶诺药业有限公司 | 2020-02-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11034696-B2 | Compounds for inhibiting LRRK2 kinase activity | LRRK2, BRSK2, MAPKAPK2 | SMN1; SMN2 285/4885CYP11B1 4166/4885CYP11B2 3678/4885 |
| US-20230029385-A1 | 2-METHYL-AZA-QUINAZOLINES | AZI2, DNMT1, TPMT | SMN1; SMN2 1633/4885CYP11B1 583/4885CYP11B2 330/4885 |
| US-20210387963-A1 | PHENYLTETRAZOLE DERIVATIVES AS PLASMA KALLIKREIN INHIBITORS | KLKB1, SERPINE1, SERPINB1 | SMN1; SMN2 4619/4885CYP11B1 976/4885CYP11B2 1128/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.